|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
140,990,000 |
Market
Cap: |
73.88(M) |
Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
52
Week Range: |
$0.2971 - $1.74 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
3 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Willoughby Scott B. |
SVP, GEN. COUNSEL & SECRETARY |
|
2024-02-24 |
4 |
D |
$1.13 |
$4,948 |
D/D |
(4,379) |
839,883 |
|
- |
|
Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
|
2024-02-24 |
4 |
D |
$1.13 |
$6,186 |
D/D |
(5,474) |
851,198 |
|
- |
|
Pooler Amy |
VP, HEAD OF RESEARCH |
|
2024-02-24 |
4 |
D |
$1.13 |
$2,496 |
D/D |
(2,209) |
198,773 |
|
- |
|
Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
|
2024-02-24 |
4 |
D |
$1.13 |
$18,210 |
D/D |
(16,115) |
2,576,361 |
|
- |
|
Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
|
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000,000 |
2,592,476 |
|
- |
|
Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
|
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
712,500 |
843,505 |
|
- |
|
Willoughby Scott B. |
SVP, GEN. COUNSEL & SECRETARY |
|
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
712,500 |
844,262 |
|
- |
|
Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
|
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
712,500 |
856,672 |
|
- |
|
Pooler Amy |
VP, HEAD OF RESEARCH |
|
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
200,982 |
|
- |
|
Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
|
2023-11-25 |
4 |
D |
$0.38 |
$508 |
D/D |
(1,329) |
126,762 |
|
- |
|
Fontenot Jason D. |
SVP, Chief Scientific Officer |
|
2023-11-25 |
4 |
D |
$0.38 |
$394 |
D/D |
(1,030) |
136,270 |
|
- |
|
Duraibabu Prathyusha |
SVP, Chief Financial Officer |
|
2023-11-25 |
4 |
D |
$0.38 |
$508 |
D/D |
(1,329) |
131,005 |
|
- |
|
Dubois-Stringfellow Nathalie |
SVP-Chief Development Officer |
|
2023-11-25 |
4 |
D |
$0.38 |
$559 |
D/D |
(1,462) |
139,172 |
|
- |
|
Pooler Amy |
VP, Head of Research |
|
2023-11-25 |
4 |
D |
$0.38 |
$187 |
D/D |
(490) |
50,982 |
|
- |
|
Mcclung David Mark |
EVP, Chief Operating Officer |
|
2023-11-25 |
4 |
D |
$0.38 |
$736 |
D/D |
(1,925) |
212,471 |
|
- |
|
Macrae Sandy |
President, CEO and Director |
|
2023-11-25 |
4 |
D |
$0.38 |
$3,978 |
D/D |
(10,411) |
592,476 |
|
- |
|
Pooler Amy |
VP, Head of ResearchOfficer |
|
2023-11-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
51,472 |
|
- |
|
Biogen Ma Inc. |
10% Owner |
|
2023-09-26 |
4 |
S |
$0.50 |
$3,000,000 |
I/I |
(6,000,000) |
17,652,466 |
|
- |
|
Macrae Sandy |
President, CEO and Director |
|
2023-08-25 |
4 |
D |
$0.77 |
$8,016 |
D/D |
(10,411) |
602,887 |
|
- |
|
Fontenot Jason D. |
SVP, Chief Scientific Officer |
|
2023-08-25 |
4 |
D |
$0.77 |
$792 |
D/D |
(1,029) |
137,300 |
|
- |
|
Duraibabu Prathyusha |
SVP, Chief Financial Officer |
|
2023-08-25 |
4 |
D |
$0.77 |
$1,023 |
D/D |
(1,329) |
132,334 |
|
- |
|
Mcclung David Mark |
EVP, Chief Operating Officer |
|
2023-08-25 |
4 |
D |
$0.77 |
$1,482 |
D/D |
(1,925) |
214,396 |
|
- |
|
Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
|
2023-08-25 |
4 |
D |
$0.77 |
$1,023 |
D/D |
(1,329) |
128,091 |
|
- |
|
Dubois-Stringfellow Nathalie |
SVP-Chief Development Officer |
|
2023-08-25 |
4 |
D |
$0.77 |
$1,126 |
D/D |
(1,462) |
140,634 |
|
- |
|
Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
|
2023-08-13 |
4 |
D |
$1.08 |
$933 |
D/D |
(864) |
129,420 |
|
- |
|
521 Records found
|
|
Page 2 of 21 |
|
|